EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

Creative Biolabs has invited Dr. Magnus A.G. Hoffmann to walk us through the application of hybrid mRNA technology in vaccine development, strategies for optimizing hybrid mRNA vaccines, and the use of this technology in developing pan-coronavirus vaccines.